2025-03-24 02:08:38
Latest Post
NCC Limited receives contract worth Rs. 1480.34 crore
IIFL Capital Services Ltd announces changes in top management
EPACK Durable Ltd receives approval for disbursement of 2nd tranche of incentive under PLI Scheme for White Goods
Ola Electric Commences Deliveries of S1 Gen 3 Scooters Across India
Raymond Ltd to invest an amount up to Rs. 65 crore in Ten X Realty East Ltd
Stock Report
Nath Bio-Genes India Ltd Q2 FY2024-25 consolidated profit at Rs. 1.11 crore
Posted On : 2024-10-24 00:32:08( TIMEZONE : IST )
Nath Bio-Genes (India) Limited has reported Consolidated financial results for the period ended September 30, 2024.
Financial Results (Q2 FY2025) - QoQ Comparison
The company has reported total income of Rs. 32.1926 crores during the period ended September 30, 2024 as compared to Rs. 243.8751 crores during the period ended June 30, 2024.
The company has posted net profit / (loss) of Rs. 1.1133 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs. 33.3549 crores for the period ended June 30, 2024.
The company has reported EPS of Rs. 0.53 for the period ended September 30, 2024 as compared to Rs. 17.49 for the period ended June 30, 2024.
| Financials | Q2 FY2025 | Q1 FY2025 | % Change |
| Total Income | ₹ 32.1926 crs | ₹243.8751 crs |  -86.80% |
| Net Profit | ₹1.1133 crs | ₹33.3549 crs | -96.66% |
| EPS | ₹0.53 | ₹17.49 | -96.97% |
Financial Results (Q2 FY2025) - YoY Comparison
The company has reported total income of Rs. 32.1926 crores during the period ended September 30, 2024 as compared to Rs.22.5677 crores during the period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.1.1133 crores for the period ended September 30, 2024 as against net profit / (loss) of Rs.1.4997 crores for the period ended September 30, 2023.
The company has reported EPS of Rs.0.53 for the period ended September 30, 2024 as compared to Rs.0.79 for the period ended September 30, 2023.
| Financials | Q2 FY2025 | Q2 FY2024 | % Change |
| Total Income | ₹ 32.1926 crs | ₹22.5677 crs |  42.65% |
| Net Profit | ₹1.1133 crs | ₹1.4997 crs | -25.77% |
| EPS | ₹0.53 | ₹0.79 | -32.91% |
Financial Results (Half Year Ended FY2025) - YoY Comparison
The company has reported total income of Rs.276.0677 crores during the 6 Months period ended September 30, 2024 as compared to Rs.257.8493 crores during the 6 Months period ended September 30, 2023.
The company has posted net profit / (loss) of Rs.34.4682 crores for the 6 Months period ended September 30, 2024 as against net profit / (loss) of Rs.34.6803 crores for the 6 Months period ended September 30, 2023.
The company has reported EPS of Rs.18.01 for the 6 Months period ended September 30, 2024 as compared to Rs.18.27 for the 6 Months period ended September 30, 2023.
| Financials | Half Year Ended FY2025 | Half Year Ended FY2024 | % Change |
| Total Income | ₹276.0677 crs | ₹257.8493 crs | 7.07% |
| Net Profit | ₹34.4682 crs | ₹34.6803 crs | -0.61% |
| EPS | ₹18.01 | ₹18.27 | -1.42% |
Shares of Nath Bio-Genes (India) Limited was last trading in BSE at Rs. 199.80 as compared to the previous close of Rs. 199.45. The total number of shares traded during the day was 3429 in over 152 trades.
The stock hit an intraday high of Rs. 207.85 and intraday low of 192.30. The net turnover during the day was Rs. 678984.00.
